nifedipine


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to nifedipine: atenolol

nifedipine

 [ni-fed´ĭ-pēn]
a calcium channel blocking agent administered orally as a coronary vasodilator in the treatment of angina pectoris; also used in the treatment of hypertension.

nifedipine

/ni·fed·i·pine/ (ni-fed´ĭ-pēn) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension.

nifedipine

(nī-fĕd′ə-pēn′)
n.
A calcium channel blocker drug, C17H18N2O6, that acts as a coronary vasodilator and is used primarily to treat hypertension and angina pectoris.

NIFEdipine

[nifed′ipēn]
a calcium channel blocker.
indications It is prescribed for the treatment of vasospastic and effort-associated angina, pulmonary hypertension, and hypertension (sustained-release form only).
contraindications Known hypersensitivity to this drug prohibits its use, and immediate-release forms should not be used to treat hypertension. The practice of using short-acting sublingual nifedipine in hypertensive emergencies or pseudoemergencies is dangerous and should be abandoned.
adverse effects Among the more serious adverse effects are hypotension, peripheral edema, palpitations, dyspnea, nausea, dizziness, flushing, and headache. When given sublingually, stroke, severe hypotension, syncope, heart block, sinus arrest, myocardial infarctions, and fetal distress are among the adverse effects reported.

nifedipine

Procardia® Cardiology A dihydropiridine CCB vasodilator used for angina, as a short-acting antihypertensive–↓ BP, resulting in a ↓ left ventricular volume and myocardial mass, ↑ ejection fraction Side effects Tachycardia, headache, peripheral edema, cerebral ischemia, stroke, severe hypotension, AMI, conduction defects, fetal distress, death. See Calcium channel blockers, Hypertension, TIBBS.

nifedipine

A CALCIUM CHANNEL BLOCKER drug used to control the symptoms of ANGINA PECTORIS and to treat high blood pressure (HYPERTENSION). It has a powerful effect in widening (dilating) arteries, including the coronary arteries, and this improves the blood supply to the heart muscle. The drug, however, causes flushing, headache, skin itching and dizziness. It is often used in combination with a BETA-BLOCKER. Nifedipine has been used effectively to prevent high altitude lung oedema, a feature of mountain sickness. The drug is on the WHO official list. Brand names are Adalat, Adipine MR, Angiopine MR, Cardilate MR, Coracten, Fortipine LA, Tensipine MR and Unipine XL.

nifedipine

calcium channel-blocking drug; may be used to treat severe perniosis, or to control pain of leiomyoma

nifedipine (nīfed´əpēn´),

n brand names: Procardia, Procardia XL;
drug class: calcium channel blocker;
action: inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, dilates coronary arteries; increases myocardial oxygen delivery in patients with vasospastic angina; dilates peripheral arteries;
uses: chronic stable angina pectoris, vasospastic angina, hypertension. Can cause gingival hyperplasia.

nifedipine

a calcium channel blocker used principally as a vasodilator.
References in periodicals archive ?
Nifedipine XL is a controlled release version of nifedipine using Penwest's TIMERx(R) oral drug delivery technology.
The Company currently markets Nifedipine ER Tablets in all three dosage strengths (30 mg, 60 mg, and 90 mg).
Teva has already introduced the 60mg version of Nifedipine XL last October.
This press release contains forward-looking statements concerning the status of certain legal proceedings concerning Elan's Nifedipine Extended-Release tablets.
market for nifedipine controlled-release product is approximately $1 billion.
Elan was the first company to file an abbreviated new drug application with the FDA for the Nifedipine Extended Release tablets, 30 mg.
Complete Global Nifedipine Industry Report 2015 is now available at http://www.
2% among the 248 women randomized to receive nifedipine.
Studies by Saita and colleagues and Borghi and colleagues both demonstrated clinical significance in increasing expulsion rates of distal ureteral stones in patients who received combined methylprednisolone and nifedipine therapy.
1,2,9) Theoretically, all the drugs of these groups can cause gingival overgrowth, but few drugs like phenytoin sodium (50%), cyclosporine (30%), nifedipine (10%), 2 are associated with high prevalence of overgrowths.
To compare EOAs effects on atrial contraction we did a series of experiments using nifedipine (MP Biomedicals, OH, USA) as a positive control.